[205] used cross‐linked multilamellar liposomal vesicles (cMLV) to deliver specific A2aR antagonist (SCH‐58261) to TME and enhanced the anti‐tumor effect in an ovarian cancer‐bearing mouse model by reactivating the tumor‐infiltrating lymphocytes (TIL) inactivated by immunosuppressive molecules such as adenosine. The gene discussed is ADORA2A; the disease is neoplasm.